NCT07158307View on ClinicalTrials.gov

Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

Enrolling by invitationOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

June 27, 2030

Study Completion Date

June 30, 2031

Conditions

Coronary Artery Disease(CAD)

Trial Locations (1)

44033

Ulsan University Hospital, Ulsan

All Listed Sponsors

lead

Genoss Co., Ltd.

INDUSTRY